Former Senator Ben Sasse Praises Daraxonrasib for Tumor Reduction
Former U.S. Senator Ben Sasse has publicly praised a new drug, daraxonrasib, for significantly reducing his pancreatic cancer tumors. In an interview with CBS News' 60 Minutes, Sasse revealed that the drug has shrunk his tumor volume by more than three-quarters over the past four months. Daraxonrasib, developed by Revolution Medicines, is currently in Phase 3 clinical trials and targets RAS-connected cancers. It is the first drug of its kind to inhibit RAS proteins, which are known to influence the development of various cancers, including pancreatic cancer. Sasse, who was diagnosed with pancreatic cancer last year, expressed hope that the drug could extend his life beyond the initial prognosis of three to four months. 
